Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study

BACKGROUND: Although the validity and safety of antipsychotic polypharmacy remains unclear, it is commonplace in the treatment of schizophrenia. This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjus...

Descripción completa

Detalles Bibliográficos
Autores principales: Misawa, Fuminari, Shimizu, Keiko, Fujii, Yasuo, Miyata, Ryouji, Koshiishi, Fumio, Kobayashi, Mihoko, Shida, Hirokazu, Oguchi, Yoshiyo, Okumura, Yasuyuki, Ito, Hiroto, Kayama, Mami, Kashima, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/
https://www.ncbi.nlm.nih.gov/pubmed/21791046
http://dx.doi.org/10.1186/1471-244X-11-118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155482/
https://www.ncbi.nlm.nih.gov/pubmed/21791046
http://dx.doi.org/10.1186/1471-244X-11-118

Ejemplares similares